Societies
FDA
bms.com

FDA Granted Breakthrough Therapy Designation for Treating NSCLC – BMS

Bristol Myers Squibb (BMS) shared a post on X:

“The FDA U.S. has granted Breakthrough Therapy Designation to our investigational EGFRxHER3 bispecific ADC for previously treated EGFR-mutant NSCLC.

Read More.”

More posts featuring Bristol Myers Squibb on OncoDaily

BMS Bristol Myers Squibb EGFR-mutant NSCLC FDA NSCLC